-
Leadership Shuffle at China’s National Health Commission: Liu Jinfeng Steps in as Deputy Director
•
The Ministry of Human Resources and Social Security has announced key leadership changes within the National Health Commission (NHC) of China. Liu Jinfeng has been appointed as the new deputy director of the NHC, succeeding Li Bin, who has been relieved of his duties. Liu Jinfeng brings a wealth of…
-
Autobio Diagnostics Partners with MBL to Advance Microbial Mass Spectrometry Technology
•
Autobio Diagnostics Co., Ltd (SHA: 603658), a prominent player in China’s in vitro diagnostic market, has announced a strategic partnership with Japan’s Medical & Biological Laboratories (MBL). This collaboration will focus on advancing technologies in the microbial mass spectrometer field, although specific financial details of the agreement have not been…
-
Yestar Healthcare’s 2024 Interim Report Reflects Impact of Volume-Based Procurement on Revenue
•
Yestar Healthcare Holdings Co., Ltd., a leading distributor and service provider for in vitro diagnostic (IVD) reagents and products in China, has released its interim report for 2024. The report indicates a 13.5% year-on-year (YOY) decrease in the company’s overall revenue for the first half of the year, amounting to…
-
Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives
•
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from two Phase III clinical trials for its drug Dupixent (dupilumab), indicating its potential for two distinct indications. The first trial, ADEPT, concentrated on the treatment of the rare skin condition bullous pemphigoid (BP), while the…
-
FDA Uncovers Data Management Failures in Medical Device Labs, Assessing Regulatory Impact
•
Medical device manufacturers relying on laboratory services for testing and validation data have come under scrutiny as the FDA reports pervasive issues in data management and quality assurance. The regulatory body conducted inspections earlier this year, uncovering systemic failures in data management, quality assurance protocols, staff training, and oversight within…
-
Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology
•
Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed in a London Stock Exchange filing its intention to pursue legal action against China’s genomics powerhouse BGI and its affiliates. The company alleges that BGI’s newly launched nanopore-based sequencing platform infringes upon or misappropriates Oxford…
-
Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a strategic partnership between its controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), and Haier Biomedical. The collaboration will focus on the integration of digitalization, automation, and artificial intelligence (AI) to enhance the digital and…
-
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
•
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial intelligence (AI), has entered into a strategic partnership with Guangzhou Jennio Biotech Co., Ltd. The collaboration aims to leverage organoid disease models and advance tumor immunotherapy drug development. Financial specifics…
